ClinicalTrials.gg
Active, not recruitingNCT06900023BEACONUpdated Nov 12, 2026

The BEACON Trial: Diagnostic Tools for Breast Lymphedema After Treatment for Breast Cancer

An observational study in Breast Edema, Breast Lymphedema and Lymphedema, Breast Cancer, sponsored by Massachusetts General Hospital. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Massachusetts General Hospital · Observational

How we know

Updated Nov 12, 2026Now Active, not recruitingPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
30
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Breast Cancer Lymphedema with a site in United States — 8 open to participants now, 10 under way, 1 of them phase 3. Breast Cancer Lymphedema · United States.

Started
2025
with 1 other
Observational
3 of 15
1 open now
Registered
14th of 15
by date
Lead sponsor
4 of 15
Massachusetts General Hospital

Among the 15 studies in Breast Cancer Lymphedema with a site in United States, this one is one of 2 that started in 2025, is one of 3 observational ones, and was the 14th registered.

Breast Cancer Lymphedema

124 studies on the registry are indexed under Breast Cancer Lymphedema; 39 are open to participants now.

Browse Breast Cancer Lymphedema studies →

Open to participants now

8 of the 15 studies in Breast Cancer Lymphedema with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Breast Cancer Lymphedema studies recruiting now, 8 (33%) set no upper age limit and 9 (38%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Breast Cancer Lymphedema with a site in United States, or all of them as a file.
02

Study summary

The goal of this observational study is to learn if participants agree to take part in the study, if the methods we are using for the study are feasible for the participants and the researchers, and to study how well two tools (tissue dielectric constant and ultrasound) measure breast edema after breast conserving surgery for breast cancer.

Participants who agree to be in the study will be asked to come in for one appointment of approximately two hours. All data will be collected during this one visit. Participants will be asked to fill out two questionnaires regarding their symptoms, and one questionnaire regarding their surgical scar. The research staff will conduct a clinical examination, measure breast edema using ultrasound and tissue dielectric constant, measure arm volume with the perometer and fluid with the SOZO, and take photographs of both breasts.

Read the detailed description

The goal of this observational study is to learn if the study protocol is feasible, if we can accrue participants easily, and to determine how well two tools (tissue dielectric constant and ultrasound) identify breast edema after breast conserving surgery for breast cancer.

Participants will be asked to attend one appointment in which all data will be collected. This will include questionnaires regarding symptoms, clinical examination, measurement of breast edema using two tools (ultrasound and tissue dielectric constant), measurement with the perometer and SOZO, and clinical photographs.

03

Conditions studied

  • Breast Edema
  • Breast Lymphedema
  • Lymphedema, Breast Cancer
  • Lymphedema

Keywords

  • Breast Edema
  • Breast Swelling
  • Breast Lymphedema
  • Breast Edema Screening
  • Breast swelling after breast cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women screened for lymphedema in the MGH Lymphedema Research Program Prospective Screening Program; and/or women treated in physical or occupational therapy for breast cancer-related conditions after breast conserving surgery.

Eligibility criteria

All participants must meet the following inclusion criteria:

  • Be a female between the ages of 18 and 85 years.
  • Have undergone breast conserving surgery +/- LN removal (sentinel lymph node (SLNB) or axillary lymph node dissection (ALND)
  • Have no residual cancer in the breast after definitive breast surgery
  • Have been treated with radiation therapy and have completed breast cancer treatment (excluding Herceptin and hormonal treatments) at MGH greater than or equal to 3 months ago.
  • Be able to read and understand English
  • Understand the proposed study and be willing and fully able to comply with the study procedures
  • Be a willing participant and be capable of giving and has given informed written consent for entry into the study

EXCLUSION CRITERIA

Participants will be excluded if they:

  • Have bilateral BC
  • Have or inflammatory BC
  • Will be excluded from the SOZO measurement of the study if they have implanted cardiac devices or neurostimulators
  • Have any medical condition that may result in breast swelling;

    • Uncontrolled congestive cardiac failure,
    • Arteriovenous haemodialysis,
    • Current infection or cellulitis of either breast.
  • Be pregnant or currently breast feeding.
  • Have a known over-active thyroid or known benign thyroid tumour
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Participants with breast edema: N=15

    This group will contain women who report breast edema and have been diagnosed with breast edema through clinical examination

  • Participants without breast edema: N=15

    These participants do not report a history of breast edema and do not have a history of breast edema.

06

What researchers measure

Primary outcomes

  1. Tissue Dielectric Constant

    A TDC interbreast ratio ≥ 1.28 in any quadrant will be used as an indicator of breast lymphedema

    Time frame: Baseline

  2. Breast Ultrasound

    Skin thickness \>1.60 mm in superior and lateral quadrants, \>2.0 mm in the medial and inferior quadrants will be used as an indicator of breast lymphedema.

    Time frame: Baseline

Secondary outcomes

  1. Patient-Reported Outcome Measures

    Breast Cancer Treatment Outcome Scale (BCTOS-12) Minimum Score = 12, Maximum Score = 48 Higher score indicates worse outcome

    Time frame: Baseline

  2. Patient-Reported Outcome Measures

    Breast-Q Version 2.0 Breast Conserving Therapy Module, Postoperative Scales i. Psychosocial Well-Being (min score 10, max score 50), higher score indicating better outcome

    Time frame: Baseline

  3. Scar Assessment Tool

    Patient and Observer Scar Scale Linear Scar Version 3.0

    Time frame: Baseline

  4. Clinical Examination of Lymphedema of the Upper Extremity Clinical Exam Tool

    This is a validated measure used to administer clinical examination of the breast, trunk and upper extremity for lymphedema

    Time frame: Baseline

  5. Clinical Examination - Pitting Edema

    The following will be assessed: * Each breast quadrant: Presence or absence of pitting edema * The participant is placed in supine. The examiner's thumb is placed firmly on the participant's skin, applying sustained pressure to the skin and superficial tissue for one minute. Upon release of the pressure, an indentation of the tissue at the test site is defined as pitting and is recorded as Yes in the relevant quadrant. If there is no change in the tissue, record No to pitting oedema.

    Time frame: Baseline

  6. Clinical Examination - Peau d'orange

    The following will be assessed: * Each breast quadrant, lateral chest wall and inframammary tissues: Presence or absence of peau d'orange * The participant is positioned sitting. The examiner slightly compresses the breast tissue between their first finger and thumb to look for the orange peel appearance to the skin. A light can be shone tangentially across the breast to assist in identifying peau d'orange.

    Time frame: Baseline

  7. Clinical Examination - Tissue fibrosis

    The following will be assessed: * Each breast quadrant: Presence or absence of tissue fibrosis * The participant is placed in supine. The examiner uses their first finger and thumb to palpate the tissue and gently pinch the tissue to assess for any tissue thickening, increased firmness or density and/or tissue retraction or fixation, compared to the equivalent tissue on the unaffected side. If the participant has had surgery on the unaffected breast (e.g. breast reduction), the tissue in the quadrant most distal to the incision site is used as the comparator tissue. N/A is marked in the table for the unaffected breast, unless the participant has had surgery on the unaffected side and tissue fibrosis is detected as a result compared to other quadrants of the unaffected breast.

    Time frame: Baseline

  8. Clinical Examination - Tenderness to palpation

    The following will be assessed: * Each breast quadrant: Presence or absence of tenderness to palpation. * The examiner will lightly palpate the tissue of each breast quadrant to see if the participant reports any pain or tenderness. Deep palpation, particularly medially in the breast, may cause tenderness in the costochondral cartilages.

    Time frame: Baseline

  9. Clinical Examination - Erythema

    The following will be assessed: \- Each breast quadrant: Presence or absence of erythema (redness of the skin)

    Time frame: Baseline

  10. Clinical Examination - Scar localization

    The following will be assessed: \- Scar measurements for the breast and axillary scars, including location (quadrant, distance from the center of the nipple to the center of the scar), scar length, width and orientation (vertical, horizontal, oblique or radial).

    Time frame: Baseline

  11. Clinical Examination - Visual fullness

    The following will be assessed: \- Lateral chest wall and inframammary tissue: The examiner will record presence or absence of visual fullness

    Time frame: Baseline

  12. Clinical Examination - Stemmer sign

    The following will be assessed: \- Lateral chest wall and inframammary tissue: Presence or absence of the Stemmer sign. The Stemmer sign is a physical examination finding used to diagnose lymphedema. If the examiner cannot pinch the skin then this positive finding is associated with lymphedema. The Stemmer sign has been found to be a sensitive predictor for primary and secondary lymphedema with moderate specificity (Goss JA, Greene AK. Sensitivity and Specificity of the Stemmer Sign for Lymphedema: A Clinical Lymphoscintigraphic Study. Plast Reconstr Surg Glob Open. 2019 Jun 25;7(6):e2295. doi: 10.1097/GOX.0000000000002295. PMID: 31624689; PMCID: PMC6635205)

    Time frame: Baseline

  13. Clinical Examination - Tissue thickening

    The following will be assessed by the examiner: \- Nipple and nipple-areolar complex: Tissue thickening on the side of surgery as compared to the unaffected side

    Time frame: Baseline

  14. Clinical Examination - Skin color changes

    The following will be assessed by the examiner: \- Nipple and nipple-areolar complex: Skin color changes as compared to the unaffected side (lighter, darker, same)

    Time frame: Baseline

  15. Patient-Reported Outcome Measures

    Breast-Q Version 2.0 Breast Conserving Therapy Module, Postoperative Scales ii. Sexual Well-Being (min score 6, max score 30), higher score indicating better outcome

    Time frame: Baseline

  16. Patient-Reported Outcome Measures

    Breast-Q Version 2.0 Breast Conserving Therapy Module, Postoperative Scales iii. Satisfaction with Breasts (min score 11, max score 44), higher score indicating better outcome

    Time frame: Baseline

  17. Patient-Reported Outcome Measures

    Breast-Q Version 2.0 Breast Conserving Therapy Module, Postoperative Scales iv. Physical Well-Being: Chest (min score 10, max score 30), higher score indicating better outcome

    Time frame: Baseline

  18. Patient-Reported Outcome Measures

    Breast-Q Version 2.0 Breast Conserving Therapy Module, Postoperative Scales v. Adverse Effects of Radiation (min score 6, max score 18), higher score indicating better outcome

    Time frame: Baseline

  19. Patient-Reported Outcome Measures

    Breast-Q Version 2.0 Breast Conserving Therapy Module, Postoperative Scales vi. Satisfaction with Information - Breast Surgeon (min score 12, max score 48), higher score indicating better outcome

    Time frame: Baseline

Other outcomes

  1. Perometry

    Perometry will be undertaken per clinical protocol to screen for arm lymphedema

    Time frame: Baseline

  2. Bioimpedance Spectroscopy (SOZO)

    Bioimpedance Spectroscopy will be undertaken per clinical protocol

    Time frame: Baseline

  3. Clinical Photographs

    Clinical photographs of each breast, repeated for the right and then the left breast, taken per study protocol 5 positions each side, including a close up photo of the breast and surgical scar.

    Time frame: Baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from May 2025 to primary completion in Feb 2026, 9 months.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Feb 2026, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2025
First posted
Mar 28, 2025
StartActual
May 5, 2025
Primary completionActual
Feb 6, 2026was Dec 2026
CompletionEst.
Dec 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Active, not recruiting
changed Nov 12, 2026
Primary completion
Dec 2026→Feb 6, 2026 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Enrolling by invitation→Active, not recruiting
    Primary completion Dec 2026→Feb 6, 2026 (now actual)
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06900023
Responsible party
Cheryl Brunelle (Physical Therapy Clinical Specialist, Associate Director, MGH Lymphedema Research Program, Massachusetts General Hospital) — Principal investigator
First posted
Mar 28, 2025
Start date
May 5, 2025
Primary completion
Feb 6, 2026
Completion
Dec 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Cheryl Brunelle, MScPT
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion